ALIF-B

AddLife is a Swedish Life Science company that owns and acquires companies in niche segments serving the healthcare and research sectors. The group operates through two main business areas: Labtech, covering Biomedical and Research and Diagnostics, and Medtech, covering Hospital and Homecare. AddLife supplies equipment, instruments, and reagents to customers in healthcare, research, universities, and the pharmaceutical and food industries across approximately 30 European countries. The company serves both private and public sector clients, offering a portfolio of self-manufactured and third-party products alongside advisory, service, and training solutions. Notable acquisitions include Edge Medical, Opitek International, and Pharmacold.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Medical Distribution Homepage add.life
Sector Healthcare IR page add.life
Tags
life science, medical equipment, laboratory reagents, diagnostics, hospital supplies, homecare, research instruments, pharmaceutical industry, food industry, technical service, training, Labtech, Medtech, Biomedical and Research, Hospital, Edge Medical, Opitek International, Pharmacold
Press page add.life/media/press-release

Metrics

Valuation  
Market cap kr 20.201B
Market cap (USD) $ 1.998B
P/E 35.94
PEG 6.82
P/BV 3.71
P/S 1.93
P/OCF 14.51
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.5%
ROI 7.1%
ROIC 9.1%
Profit margin 5.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 5.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 45.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 27
Quality score 56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 10.442B 10.286B 9.685B 9.084B 7.993B 5.273B — 2.404B 2.168B 1.76B
Net profit 562M 254M 192M 483M 720.6M 517.79M — 123M 125M 95.1M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 159.1 137.3 109.4 108.6 110 — 72.25 144 381.4 —
Price performance 12m 0.16 0.26 0.01 -0.01 -0.24 — -0.5 -0.62 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (SEK) — 755M 1.09B 1.33B 1.46B 1.53B 1.49B
↳ YoY growth +44.2% +21.8% +10.4% +4.6% -2.5%
↳ 5y CAGR +14.6%
Other receivables (SEK) — — — — 42M 135M 40M
Borrowings, current (SEK) — — — — 2.25B 803M 1.78B
Borrowings, non-current (SEK) — — — — 2.54B 3.74B 2.49B
Lease liabilities (SEK) — 233M 345M 356M 504M 531M 504M
Cash and deposits (SEK) 99.1M 216M 345M 376M 272M 331M 813M
Right-of-use assets (SEK) — — — — 490M 512M 482M
Net debt (borrowings + leases - cash) (SEK) — — — — 5.02B 4.74B 3.96B
Cash flow detail
Operating cash flow (SEK) — 950M 1.01B 909M 773M 1.1B 1.39B
Purchases of property, plant and equipment (SEK) — -62.7M -101M -213M -226M -250M -242M
Purchases of intangible assets (SEK) — -29.5M -42.5M -69M -82M -47M -42M
Change in receivables (cash effect) (SEK) — -171M 18.3M 64M -129M -28M -13M
Change in inventories (cash effect) (SEK) — -119M 52.8M -88M -30M -4M -1M
Change in payables (cash effect) (SEK) — 397M -185M -97M 95M 76M 43M
Dividends paid (cash effect) (SEK) — -56.2M -183M -243M -146M -61M -91M
Share buybacks (cash effect) (SEK) — -19.3M 0.00 -60M 0.00 — —
Interest paid (cash effect) (SEK) — — — -112M -272M -322M -224M
Income taxes paid (cash effect) (SEK) — -97M -253M -256M -210M -137M -217M
Operating cash flow before change in receivables (SEK) — 1.12B 992M 845M 902M 1.12B 1.41B
Free cash flow (OCF - PPE - intangibles) (SEK) — 858M 866M 627M 465M 798M 1.11B
Income detail
Research and development expense (SEK) — 23.9M 33.5M 81M 167M 76M 57M
↳ 5y CAGR +19.0%
Total comprehensive income (SEK) — 434M 794M 956M 148M 422M 226M
Comprehensive income to owners (SEK) — 433M 791M 953M 145M 420M 223M
Reported — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Interim Report January 1 – September 30, 2026 Bull 3 Bear 0 Results

21 October 2026

07:45

Regulatory

The positive development in the companies continues, and the pace of acquisitions is increasing_“The positive development across AddLife’s companies continues, with stronger margins, solid growth and improved cash flow. The operational improvements and strengthened balance sheet have enabled increased acquisition activity, something we have been preparing for a long time.”_Fredrik Dalborg, President and CEO
AddLife´s interim report for Q3 2026 is now available online at the company website. The interim report can be downloaded in pdf version. Visit https://reports-en.add.life/interim-report-q3-2026

THIRD QUARTER

  • Net sales increased by 7 percent to SEK 2,599 million (2,429). Adjusted for operations divested in December 2025, organic growth amounted to 4 percent and acquired growth amounted to 3 percent. 
  • Adjusted EBITA increased by 11 percent to 298 (270), corresponding to an adjusted EBITA margin of 11.5 percent (11.1). Adjusted EBITA excludes the remeasurement of contingent considerations of SEK 32 million.
  • EBITA amounted to SEK 330 million (270).
  • Profit after tax increased by 56 percent to SEK 128 million (82).
  • Earnings per share amounted to SEK 1.05 (0.66). 
  • Cash flow from operating activities increased by 62 percent to SEK 236 million (145).
  • During the quarter, the acquisition of Unicam Sistemas Analíticos Lda, Portugal, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 110 million.
  • After the end of the interim period, the acquisition of Lehnen GmbH, Germany, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 55 million.

JANUARY – SEPTEMBER, 2026

  • Net sales increased by 3 percent to SEK 7,965 million (7,709). Adjusted for operations divested in December 2025, organic growth amounted to 4 percent, acquired growth amounted to 2 percent.
  • Adjusted EBITA increased by 6 percent to 972 (920), corresponding to an adjusted EBITA margin of 12.2 percent (11.9). Adjusted EBITA excludes the remeasurement of contingent considerations of SEK 32 million.
  • EBITA amounted to SEK 1,004 million (920).
  • Profit after tax increased by 28 percent to SEK 386 million (302).
  • Earnings per share amounted to SEK 3.15 (2.47). For the latest 12-month period, earnings per share amounted to 5.28 (3.23). 
  • Cash flow from operating activities amounted to SEK 505 million (504).
  • The equity ratio was 44 percent (43).
  • Return on working capital (P/WC) amounted to 63 percent (62).
  • Three acquisitions were completed during and one acquisition after the interim period. The acquisitions are expected to contribute annual net sales of approximately SEK 350 million.

Stockholm, October 21, 2026

AddLife AB (publ)

Interim Report January 1 – June 30, 2026 Bull 3 Bear 0 Results

16 July 2026

07:45

Regulatory

Positive development across AddLife’s companies
“AddLife’s companies are performing well across the board, with stronger margins, good growth and increased cash flow. Our improvement efforts are yielding clear results, and our recently acquired companies are making a significant contribution to _earnings growth. At the same time, we are actively pursuing further acquisitions.”_Fredrik Dalborg, President and CEO
AddLife´s interim report for Q2 2026 is now available online at the company website. The interim report can be downloaded in pdf version. Visit https://reports-en.add.life/interim-report-q2-2026

SECOND QUARTER

  • Net sales increased by 6 percent to SEK 2,721 million (2,578). Adjusted for operations divested in December 2025, organic growth amounted to 4 percent and acquired growth amounted to 3 percent.
  • EBITA increased by 11 percent to SEK 342 million (307), corresponding to an EBITA margin of 12.6 percent (11.9).
  • Profit after tax increased by 30 percent to SEK 130 million (100).
  • Earnings per share amounted to SEK 1.06 (0.83).
  • Cash flow from operating activities amounted to SEK 165 million (119).
  • During the quarter, the acquisition of CoaChrom Diagnostica GmbH, Austria, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 110 million.

JANUARY – JUNE, 2026

  • Net sales increased by 2 percent to SEK 5,366 million (5,280). Adjusted for operations divested in December 2025, organic growth amounted to 3 percent, acquired growth amounted to 2 percent, and exchange rate effects had a negative impact of 2 percent.
  • EBITA increased by 4 percent to SEK 674 million (650), corresponding to an EBITA margin of 12.6 percent (12.3). Exchange rate effects had a negative impact of 2 percent on EBITA.
  • Profit after tax increased by 17 percent to SEK 258 million (220).
  • Earnings per share amounted to SEK 2.11 (1.81). For the latest 12‑month period, earnings per share amounted to 4.89 (2.76).
  • Cash flow from operating activities amounted to SEK 269 million (359).
  • The equity ratio was 43 percent (43).
  • Return on working capital (P/WC) amounted to 61 percent (62).
  • During the interim period, two acquisitions were completed. The acquisitions are expected to contribute annual net sales of approximately SEK 185 million.

Stockholm, July 16, 2026

AddLife AB (publ)

Biolin Scientific elevates the Sigma force tensiometer line with a new product family

Biolin Scientific 08/06/2026

Biolin Scientific is proud to introduce the new Sigma family of force tensiometers, product line, designed to meet a broader range of surface and interfacial tension measurement needs.

Sigma Group 1

Biolin Scientific is proud to introduce the new Sigma family of force tensiometers, product line, designed to meet a broader range of surface and interfacial tension measurement needs. Built for both routine quality control and advanced research, the new Sigma family gives researchers and quality control professionals greater flexibility, performance, and confidence in their measurements.

“Sigma has long been a trusted name in force tensiometry. This launch is about taking that legacy further,” says Susanna Laurén, Marketing Director at Biolin Scientific. “Our customers work in different environments, from everyday quality control to demanding research applications. With the new Sigma family, we can offer an instrument that better matches their specific needs while maintaining the reliability they expect from Sigma.”

“Instruments share a consistent design language and user experience, making it easy for users to move between systems. Across the range, Sigma continues to deliver the measurement performance, usability, and reliability our customers depend on.” Bo Chang, Technical Product Manager at Biolin Scientific.

With the launch of the new Sigma family, Biolin Scientific strengthens its position as a premium provider of force tensiometry solutions. This line reflects the company’s commitment to developing instruments that are intuitive to use, versatile in application, and built to support reliable results across both industrial and research settings.

News from AddLife’s subsidiaries

![Linkedin Video 116](https://www.add.life/media/c14g1jzk/linkedin-video_116.jpg)

13 October 2026

World Thrombosis Day 2026 - Awareness is the first step to prevention

Every year on October 13th, World Thrombosis Day raises awareness of a condition that remains widely overlooked, despite its significant impact on global health.

CoaChrom

![Banner New Website Live Bio Connect](https://www.add.life/media/ysmboom5/banner-new-website-live-bio-connect.png)

06 May 2026

Get the Most Out of the New Bio-Connect Website

The new Bio-Connect website is live, designed to help you find products, services and scientific content faster so you can focus on advancing your research.

Bio-Connect

Back to top

AddLife Logo

AddLife AB

Brunkebergstorg 5

[Tel: 08-420 03 830](tel:08-420 03 830) Contact

LinkedIn


Privacy Policy and Cookies

English

Swedish

×

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy. Read more

Save & Close

Accept all

Decline all

Show details Hide details

Prompts

AddLife (ticker ALIF-B), listed in Sweden.

ETFs Holding AddLife

ETF Weight in ETF Shares Market value As of
AVDS 0.09% 17,546 $ 314.262K Nov 16, 2026
DFIS 0.06% 179,137 $ 3.252M Nov 12, 2026
DFIC 0.01% 110,331 $ 2.003M Nov 12, 2026
DXIV 0.01% 1,724 $ 31.293K Nov 12, 2026
DFSI 0.01% 7,827 $ 142.069K Nov 12, 2026
DFAX 0.01% 54,882 $ 996.17K Nov 12, 2026
DFAI 0.01% 66,311 $ 1.204M Nov 12, 2026
AVDE 0.00% 6,029 $ 107.984K Nov 16, 2026
AVSD 0.00% 403 $ 7,218.03 Nov 16, 2026